808 related articles for article (PubMed ID: 1525588)
21. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
22. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
[TBL] [Abstract][Full Text] [Related]
23. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
Dederichs B; Dietlein M; Jenniches-Kloth B; Schmidt M; Theissen P; Moka D; Schicha H
Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):366-70. PubMed ID: 16915539
[TBL] [Abstract][Full Text] [Related]
24. Hyperthyroidism. Current treatment guidelines.
Gittoes NJ; Franklyn JA
Drugs; 1998 Apr; 55(4):543-53. PubMed ID: 9561343
[TBL] [Abstract][Full Text] [Related]
25. Graves' disease in adults Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy.
Prescrire Int; 2017 Mar; 26(180):72-77. PubMed ID: 30730622
[TBL] [Abstract][Full Text] [Related]
26. Endocrine ophthalmopathy and radioiodine therapy.
Karlsson FA
Acta Oncol; 2006; 45(8):1046-50. PubMed ID: 17118837
[TBL] [Abstract][Full Text] [Related]
27. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study.
Ljunggren JG; Törring O; Wallin G; Taube A; Tallstedt L; Hamberger B; Lundell G
Thyroid; 1998 Aug; 8(8):653-9. PubMed ID: 9737359
[TBL] [Abstract][Full Text] [Related]
28. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.
Kung AW; Yau CC; Cheng A
J Clin Endocrinol Metab; 1994 Aug; 79(2):542-6. PubMed ID: 7913934
[TBL] [Abstract][Full Text] [Related]
29. Treating severe Graves' ophthalmopathy.
Bartalena L; Marcocci C; Pinchera A
Baillieres Clin Endocrinol Metab; 1997 Oct; 11(3):521-36. PubMed ID: 9532337
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
31. [Graves-Basedow's disease: effect of treatment methods for hyperthyroidism on the course of ophthalmopathy].
Myśliwiec J; Grygorczuk S; Kinalska I
Pol Arch Med Wewn; 2000 Jul; 104(1):413-8. PubMed ID: 11303333
[TBL] [Abstract][Full Text] [Related]
32. (131)I and thyroid-associated ophthalmopathy.
Rasmussen AK; Nygaard B; Feldt-Rasmussen U
Eur J Endocrinol; 2000 Aug; 143(2):155-60. PubMed ID: 10913933
[TBL] [Abstract][Full Text] [Related]
33. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
[TBL] [Abstract][Full Text] [Related]
34. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
35. [Autoimmune diseases of the thyroid gland].
Allelein S; Feldkamp J; Schott M
Internist (Berl); 2017 Jan; 58(1):47-58. PubMed ID: 28074218
[TBL] [Abstract][Full Text] [Related]
36. Radioactive iodine therapy in Graves' hyperthyroidism.
Sankar R; Sripathy G
Natl Med J India; 2000; 13(5):246-51. PubMed ID: 11190053
[TBL] [Abstract][Full Text] [Related]
37. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.
Moleti M; Mattina F; Salamone I; Violi MA; Nucera C; Baldari S; Lo Schiavo MG; Regalbuto C; Trimarchi F; Vermiglio F
Thyroid; 2003 Jul; 13(7):653-8. PubMed ID: 12964971
[TBL] [Abstract][Full Text] [Related]
38. Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy.
Kurihara H
Thyroid; 2002 Mar; 12(3):265-7. PubMed ID: 11952051
[TBL] [Abstract][Full Text] [Related]
39. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids.
Menconi F; Marinò M; Pinchera A; Rocchi R; Mazzi B; Nardi M; Bartalena L; Marcocci C
J Clin Endocrinol Metab; 2007 May; 92(5):1653-8. PubMed ID: 17299076
[TBL] [Abstract][Full Text] [Related]
40. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves' disease.
Abe Y; Sato H; Noguchi M; Mimura T; Sugino K; Ozaki O; Yoshimura H; Ito K
World J Surg; 1998 Jul; 22(7):714-7. PubMed ID: 9606287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
